Search results for "cost"
showing 10 items of 5421 documents
Adherence issues related to sublingual immunotherapy as perceived by allergists.
2010
Silvia Scurati1, Franco Frati1, Gianni Passalacqua2, Paola Puccinelli1, Cecile Hilaire1, Cristoforo Incorvaia3, Italian Study Group on SLIT Compliance 1Scientific and Medical Department, Stallergenes, Milan, Italy; 2Allergy and Respiratory Diseases, Department of Internal Medicine, Genoa; 3Allergy/Pulmonary Rehabilitation, ICP Hospital, Milan, ItalyObjectives: Sublingual immunotherapy (SLIT) is a viable alternative to subcutaneous immunotherapy to treat allergic rhinitis and asthma, and is widely used in clinical practice in many European countries. The clinical efficacy of SLIT has been established in a number of clinical trials and meta-analyses. However, because SLIT is self-administered…
Patient perspectives in the management of asthma: improving patient outcomes through critical selection of treatment options
2010
Asthma is a chronic inflammatory disorder of the airways that requires long-term treatment, the goal of which is to control clinical symptoms for extended periods with the least possible amount of drugs. International guidelines recommend the addition of an inhaled long-acting beta2-agonist (LABA) to a low- to medium-dose inhaled corticosteroid (ICS) when low doses of ICS fail to control asthma symptoms. The fixed combined administration of ICS/LABA improves patient compliance, reducing the risk of therapy discontinuation. The relative deposition pattern of the inhaled drug to the target site is the result of a complex interaction between the device used, the aerosol formulation and the pat…
Deflazacort in Duchenne dystrophy: Study of long-term effect
1994
A randomized double-blind controlled trial of deflazacort was conducted in 28 Duchenne muscular dystrophy patients either treated with deflazacort 2.0 mg/kg alternate-day therapy or placebo. The deflazacort group showed significant improvement in climbing stairs (P < 0.01), in rising from a chair, Gower's maneuver, and walking (P < 0.0025) after 6 months of treatment. After 1 year, all the above changes remained significantly improved and the MRC index was significantly better (P < 0.05) in the treated group. After 2 years, a significant change was found in the MRC index: higher scores in walking, chair rising (P < 0.02), and grade and time of Gower's maneuver (P < 0.05) were found. The mea…
Chelation treatment in sickle-cell-anaemia: much ado about nothing?
2011
Summary Blood transfusions may prevent and treat serious complications related to sickle-cell disease (SCD) when performed according to specific guidelines. However, blood transfusion requirements in SCD inevitably lead to increased body iron burden. An adequate chelation treatment may prevent complications and reduce morbidity and mortality. This review evaluates the effectiveness, safety and costs of chelation treatment. The included trials were examined according to the recommendations of the American College of Cardiology (ACC) and the American Heart Association (AHA). Overall, 14 trials and a total of 502 patients with SCD were included in this review. Deferoxamine alone (s.c. or i.v.)…
Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (…
2016
Background: RES reduced exacerbation frequency and improved lung function and asthma control in pts with inadequately controlled asthma and elevated blood eosinophils (EOS) in two PBO-controlled, phase 3 trials (Castro et al. Lancet Resp Med 2015). Aims/objectives: To determine the efficacy of RES in asthma pts stratified by GINA Step 4 (G4) and Step 5 (G5) categories of asthma severity. Methods: Pooled data from two 52-week, PBO-controlled trials of RES (3mg/kg IV Q4W) in pts with inadequately controlled asthma and blood EOS ≥400/µL on inhaled corticosteroid (ICS) ± another controller; primary results have been reported. Current analysis includes pts stratified by G4 (medium/high-dose ICS …
Reducing the burden of Herpes Zoster in Italy.
2015
Herpes Zoster (HZ) is a viral disease with painful neuro-dermatologic manifestations. Incidence increases with age. In Italy, the estimated incidence is 6.3 cases/1000 person/year; hospital admissions are less than 2%, 69% in patients aged over 65 years. The most frequent complication of HZ is Post-Herpetic Neuralgia (PHN) characterized by metameric pain, allodynia, and hyperalgesia. In Italy 20.6% and 9.2% of HZ patients experience PHN after 3 and 6 months, respectively. Available antiviral and analgesic treatments are relatively unsatisfactory in reducing pain and length of the disease. Prevention has recently become possible with the live attenuated vaccine Oka/Merck. Clinical studies sh…
Rotavirus gastroenteritis: epidemiological, clinical, therapeutic aspects and economic implications
2013
Results 114 cases were diagnosed with rotavirus gastroenteritis in 2011 and 122 cases in 2012, frequently in the colder months, sex ratio M/F 1.42/1 in 2011, 1.18/1 in 2012 and in the age group 1-3 (58.90% of cases). The clinical severity was assessed by Vesikari score: 91 cases admitted in 2011 (79.82%) and 112 cases admitted in 2012 (91.80%) presenting a medium/severe score. 15 cases presented neurological symptoms and also 15 cases had renal failure. Among the electrolyte disorders the most commonly found was hyponatremia ( 150mEq/L). The hospitalization costs of rotavirus gastroenteritis cases ranged from 58.60€ to 5345 RON (1243.02€).
Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy
2016
ABSTRACT Objective: To evaluate the cost-effectiveness of bedaquiline plus background drug regimens (BR) for multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) in Italy. Methods: A Markov model was adapted to the Italian setting to estimate the incremental cost-effectiveness ratio (ICER) of bedaquiline plus BR (BBR) versus BR in the treatment of MDR-TB and XDR-TB over 10 years, from both the National Health Service (NHS) and societal perspective. Cost-effectiveness was evaluated in terms of life-years gained (LYG). Clinical data were sourced from trials; resource consumption for compared treatments was modelled according to advice from an expert c…
Corrected whole blood biomarkers - the equation of Dill and Costill revisited.
2018
Abstract An exercise bout or a dehydration often causes a reduction in plasma volume, which should be acknowledged when considering the change in biomarkers before and after the plasma changing event. The classic equation from Dill and Costill (1974, J. Appl. Physiol., 37, 247–248) for plasma volume shift is usually utilized in such a case. Although this works well with plasma and serum biomarkers, we argue in this note that this traditional approach gives misleading results in the context of whole blood biomarkers, such as lactate, white cells, and thrombocytes. In this study, we demonstrate that to calculate the change in the total amount of circulating whole blood biomarker, one should u…
A systematic review of physical fitness, physiological demands and biomechanical performance in equestrian athletes
2012
This article presents a systematic review of the literature investigating physical fitness, physiological demands and biomechanical performance in equestrian athletes. Three databases (SportsDiscus, CAB abstracts and PubMed) were searched to identify the literature. The main search term of ‘horse-riding’ was combined with eleven specific keywords (‘fitness’, ‘physiology’, ‘biomechanics’, ‘equestrian’, ‘athlete’, ‘co-ordination’, ‘heart rate’, ‘oxygen consumption’ ‘kinematic’ ‘EMG’ and ‘skill’). Exclusion criteria were: conference proceedings, abstracts, theses, and non-peer reviewed articles. Subsequently, 15 peer-reviewed papers were identified and included within this review. The main re…